A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
Dasatinib has been studied across 18 research domains including 🔬 Oncology, 🫁 Respiratory, ❤️ Cardiovascular, 🛡️ Immunity, ⏳ Longevity & Aging. The primary research focus is 🔬 Oncology with 35% of studies addressing this area.
The following compounds share molecular targets with Dasatinib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Dasatinib is generated deterministically from 481 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.